| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Obstetrics and Gynecology (G.G., V.R., F.B., A.R., M.M.) and of Internal Medicine (R.F.N., P.C.-P.), University of Torino, 10126 Torino, Italy; Carl Von Linne Kliniken (J.H.), 75183 Uppsala, Sweden; and Metabolic Unit (G.P.), Institute of Biomedical Engineering, National Research Council, 35127 Padova, Italy
Address all correspondence and requests for reprints to: Gianluca Gennarelli, Department of Obstetrics and Gynecology, via Ventimiglia 3, Torino 10100, Italy. E-mail: gennarelligl{at}libero.it.
Insulin resistance and hyperinsulinemia are often considered intrinsic features of the polycystic ovary syndrome (PCOS). Nevertheless, conflicting results of insulin sensitivity and secretion have been obtained in the subgroup of normal-weight women with PCOS. Differences in body composition, ethnicity, and diet composition and a family history of metabolic diseases may act as confounding variables in women with PCOS. In the present study, insulin sensitivity and secretion were estimated by an iv glucose tolerance test (IVGTT), analyzed by minimal models, in 20 normal-weight healthy women with PCOS and no family history of type 2 diabetes mellitus and in 20 normally ovulating women, matched for age and body mass index. Insulin sensitivity [mean (95% confidence intervals); PCOS 4.0 (2.85.1) vs. controls 4.5 (3.55.4) 104 min1/µU·ml], and insulin secretion, expressed as the acute insulin response to glucose [PCOS 3.7 (3.34.2) vs. controls 3.7 (3.44.0) µU/ml] were similar in the two groups. The women with PCOS showed an increased proportion of total body fat (PCOS 29% vs. controls 27.2%; P < 0.01). They also showed decreased glucose effectiveness, i.e. the proportion of glucose uptake independent from insulin activity [PCOS 2.6 (2.13.0) vs. controls 3.8 (3.04.6) mg x 100 min1; P = 0.01]. The levels of insulin sensitivity and of glucose effectiveness did not correlate in either group. Whether the isolated finding of decreased glucose effectiveness could reflect an early stage in the development of the metabolic aberrations often associated with the syndrome remains to be clarified.
This article has been cited by other articles:
![]() |
P. F. Svendsen, L. Nilas, K. Norgaard, J.-E. B. Jensen, and S. Madsbad Obesity, body composition and metabolic disturbances in polycystic ovary syndrome Hum. Reprod., September 1, 2008; 23(9): 2113 - 2121. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |